Synaptic biomarkers in Alzheimer's disease dementia and mild cognitive impairment: A systematic review and meta-analysis
Blood and brain fluid markers of nerve cell damage now provide a validated toolkit for improving early Alzheimer's diagnosis and trial design.
A systematic review and meta-analysis of 65 study cohorts identified eight CSF and three blood-based synaptic biomarkers — including SNAP-25 and GAP-43 as most robust — consistently altered in Alzheimer's disease dementia and mild cognitive impairment. These findings provide a comprehensive validated landscape of synaptic biomarkers that may enrich AD clinical trial design, improve early diagnosis, and serve as targets for neuroprotective interventions.
What the study was
- Study design
- Systematic review and meta-analysis
- Population
- AD dementia and MCI patients (65 study cohorts included in meta-analysis)
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Alzheimer's & Dementia
Why it surfaced
Comprehensive meta-analysis (65 cohorts) of emerging synaptic AD biomarkers beyond amyloid/tau; Alzheimer's & Dementia flagship; blood-based markers (SNAP-25, GAP-43) have translational relevance for non-invasive AD diagnostics and trial enrichment
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.